Evidence map›Paper›PMID 27687228›Full record

ArticleJournal of microbiology (Seoul, Korea)2016

RraAS2 requires both scaffold domains of RNase ES for high-affinity binding and inhibitory action on the ribonucleolytic activity.

Jihune Heo, Daeyoung Kim, Minju Joo, Boeun Lee, Sojin Seo, Jaejin Lee, Saemee Song, Ji-Hyun Yeom, Nam-Chul Ha, Kangseok Lee

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of microbiology (Seoul, Korea), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Frontiers in microbiology · 2023
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Jihune HeoDepartment of Life Science, Chung-Ang University, Seoul, 06974, Republic of Korea.
Daeyoung KimDepartment of Life Science, Chung-Ang University, Seoul, 06974, Republic of Korea.
Minju JooDepartment of Life Science, Chung-Ang University, Seoul, 06974, Republic of Korea.
Boeun LeeDepartment of Life Science, Chung-Ang University, Seoul, 06974, Republic of Korea.
Sojin SeoDepartment of Life Science, Chung-Ang University, Seoul, 06974, Republic of Korea.
Jaejin LeeDepartment of Life Science, Chung-Ang University, Seoul, 06974, Republic of Korea.
Saemee SongDepartment of Agricultural Biotechnology, Seoul National University, Seoul, 08826, Republic of Korea.
Ji-Hyun YeomDepartment of Life Science, Chung-Ang University, Seoul, 06974, Republic of Korea.
Nam-Chul HaDepartment of Agricultural Biotechnology, Seoul National University, Seoul, 08826, Republic of Korea.
Kangseok LeeDepartment of Life Science, Chung-Ang University, Seoul, 06974, Republic of Korea. kangseok@cau.ac.kr.
Chung-Ang University · KRSeoul National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RraA is a protein inhibitor of RNase E (Rne), which catalyzes the endoribonucleolytic cleavage of a large proportion of RNAs in Escherichia coli. The antibiotic-producing bacterium Streptomyces coelicolor also contains homologs of RNase E and RraA, designated as RNase ES (Rns), RraAS1, and RraAS2, respectively. Here, we report that RraAS2 requires both scaffold domains of RNase ES for high-affinity binding and inhibitory action on the ribonucleolytic activity. Analyses of the steady-state level of RNase E substrates indicated that coexpression of RraAS2 in E. coli cells overproducing Rns effectively inhibits the ribonucleolytic activity of full-length RNase ES, but its inhibitory effects were moderate or undetectable on other truncated forms of Rns, in which the N- or/and C-terminal scaffold domain was deleted. In addition, RraAS2 more efficiently inhibited the in vitro ribonucleolytic activity of RNase ES than that of a truncated form containing the catalytic domain only. Coimmunoprecipitation and in vivo cross-linking experiments further showed necessity of both scaffold domains of RNase ES for high-affinity binding of RraAS2 to the enzyme, resulting in decreased RNA-binding capacity of RNase ES. Our results indicate that RraAS2 is a protein inhibitor of RNase ES and provide clues to how this inhibitor affects the ribonucleolytic activity of RNase ES.

Indexed as

Bacterial ProteinsCatalytic DomainEndoribonucleasesEscherichia coliEscherichia coli ProteinsProtein BindingRNA, BacterialRNA StabilityStreptomyces coelicolorBacterial ProteinsEndoribonucleasesEscherichia coli Proteinsribonuclease ERNA, BacterialRraA protein, E coliRNase ESRNA stabilityRraAS2Streptomyces coelicolor

Identifiers

PMID27687228
OpenAlexW2525996364

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.